Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMMLESX)

Drug Name

ND1251 Drug Info

Synonyms

JLFMYEAXZNPWBK-REWPJTCUSA-N; Ro64-6198; Ro-64-6198; CHEMBL2088034; Ro-646198; Ro 64-6198; GTPL1684; SCHEMBL2240259; ZINC3963671; BDBM50420802; Ro646198; (1S,3aS)-8-(2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza-spiro[45]decan-4-one

Indication

Disease Entry	ICD 11	Status	REF
Depression	6A70-6A7Z	Discontinued in Phase 1	[1]

Cross-matching ID

PubChem CID: 9844019
CAS Number: CAS 280783-56-4
TTD Drug ID: DMMLESX

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Preclinical Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Nociceptin receptor (OPRL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMX-53	DMZUAJ4	Atopic dermatitis	EA80	Phase 2	[4]
SER-100	DMDW5ZC	Heart failure	BD10-BD13	Phase 2	[5]
BTRX-246040	DMA9238	Major depressive disorder	6A70.3	Phase 2	[6]
LY-2940094	DMB5L6Q	Major depressive disorder	6A70.3	Phase 2	[7]
NOCICEPTIN	DMUPA7C	Headache	8A80-8A84	Phase 1	[8]
JTC-801	DMV3UN4	Pain	MG30-MG3Z	Discontinued in Phase 2	[9]
ATI-17000	DMZJVR5	Irritable bowel syndrome	DD91.0	Preclinical	[10]
4-phenyl-1-(1-phenylbutyl)piperidin-4-ol	DMVCIJB	Discovery agent	N.A.	Investigative	[11]
1-(dio-tolylmethyl)-4-phenylpiperidin-4-ol	DMLYO8P	Discovery agent	N.A.	Investigative	[11]
1-benzhydryl-4-ethoxy-4-phenylpiperidine	DM6PIL2	Discovery agent	N.A.	Investigative	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Nociceptin receptor (OPRL1)	TTNT7K8	OPRX_HUMAN	Agonist	[2]
Sphingomyelin phosphodiesterase 4 (SMPD4)	TTZSJIV	NSMA3_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020720)
2	The nociceptin receptor as a potential target in drug design. Drug News Perspect. 2001 Aug;14(6):335-45.
3	CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
4	Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92.
5	Clinical pipeline report, company report or official report of Serodus ASA.
6	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7	Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs. Biochemical Pharmacology Volume 95, Issue 2, 15 May 2015, Pages 81-97.
8	Binding and in vitro activities of peptides with high affinity for the nociceptin/orphanin FQ receptor, ORL1. J Pharmacol Exp Ther. 1997 Nov;283(2):735-41.
9	Nociceptin receptor antagonist JTC-801 inhibits nitrous oxide-induced analgesia in mice. J Anesth. 2009;23(2):301-3.
10	Nocistatin and nociceptin given centrally induce opioid-mediated gastric mucosal protection. Peptides. 2008 Dec;29(12):2257-65.
11	Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.